Prevention of tick-borne diseases

Medical Clinics of North America

Volumn 86, Issue 2, 2002, Pages 219-238

  Wilson, Mary Elizabeth ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MOUNT AUBURN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; DOXYCYCLINE; LYME DISEASE VACCINE; PENICILLIN G; TETRACYCLINE;

ARTHRALGIA; BIOLOGY; BLOOD; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; ECOLOGY; HOST PARASITE INTERACTION; HUMAN; INFECTION PREVENTION; INSECT CONTROL; IXODES SCAPULARIS; LYME DISEASE; MYALGIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TICK; TICK BITE; TICK BORNE DISEASE;

EID: 0036223769     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(03)00084-1     Document Type: Review

References (107)

1. The value of early treatment of deer tick bite for the prevention of Lyme disease
2. Immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis
3. Reduction of immature Ixodes scapularis (Acari: Ixodidae) in woodlots by application of desiccant and insecticidal soap formulations
4. Tick-borne encephalitis vaccine
5. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old
6. Lyme disease knowledge, attitudes, and behaviors - Connecticut, 1992
7. Lyme disease - United States, 1999
8. Recommendations for the use of Lyme disease vaccine: Recommendations of the Advisory Committee on Immunization Practices
9. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi
10. A prospective study of tick bites in an endemic area for Lyme disease
11. Occurrence of severe destructive Lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with Borrelia burgdorferi
12. Residential setting as a risk factor for Lyme disease in a hyperendemic region
13. Reduction of nymphal Ixodes dammini (Acari: Ixodidae) in a residential suburban landscape by area application of insecticides
14. Geographic risk for Lyme disease and human granulocytic ehrlichiosis in southern New York state
15. Reduced abundance of Ixodes scapularis (Acari: Ixodidae) and Lyme disease risk by deer exclusion
16. Co-infection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis
17. Reported distribution of Ixodes scapularis and Ixodes pacificus (Acari: Ixodidae) in the United States
18. Growth and migration of Borrelia burgdorferi in Ixodes ticks during blood feeding
19. Influence of outer surface protein A antibody in Borrelia burgdorferi within feeding ticks
20. Effect of tick removal on transmission of Borrelia burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis nymphs
21. Landscape characterization of peridomestic risk for Lyme disease using satellite imagery
22. Increase in abundance in immature Ixodes scapularis (Acari: Ixodidae) in an emergent Lyme disease endemic area
23. Prevalence of Ixodes dammini near the homes of Lyme disease patients in Westchester County, New York
24. Accuracy of tick identification in a Lyme disease endemic area
25. Duration of tick bites in a Lyme disease-endemic area
26. Temporal relation between Ixodes scapularis abundance and risk for Lyme disease associated with erythema migrans
27. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children
28. Attachment sites of four tick species (Acari: Ixodidae) parasitizing humans in Georgia and South Carolina
29. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA
30. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice
31. Tick bites in an endemic setting - Problematic use of serologic testing and prophylactic antibiotic therapy
32. Mosquitoes and mosquito repellents: A clinician's guide
33. Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii
34. Transmission risk of Lyme disease and implications for tick management
35. Predicting Ixodes scapularis abundance on white-tailed deer using geographic information systems
36. Environmental risk factors for Lyme disease identified with geographic information systems
37. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with Lyme disease spirochete, Borrelia burgdorferi
38. Short report: The safety and toxicity of insect repellents
39. Association of treatment-resistant chronic Lyme arthritis with HLA-DR 4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi
40. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine
41. Feasibility of controlling Ixodes scapularis ticks (Acari: Ixodidae), the vector of Lyme disease, by parasitoid augmentation
42. Concurrent Lyme disease and babesiosis: Evidence for increased severity and duration of illness
43. Rapid emergence of a focal epidemic of Lyme disease in coastal Massachusetts
44. Performance of a Borrelia burgdorferi bacterin in borreliosis-endemic areas
45. Seroprotective groups of Lyme borreliosis spirochetes from North America and Europe
46. Prevention of Lyme disease after tick bites: A cost-effectiveness analysis
47. Genetic heterogeneity of Borrelia burgdorferi in the United States
48. Risk of infection from and treatment of tick bite
49. Landscape ecology of Lyme disease in a residential area of Westchester County, New York
50. Cost-effectiveness of a vaccine against Lyme disease in humans
51. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A Lyme disease vaccination
52. Simulation of blacklegged tick (Acari: Ixodidae) population dynamics and transmission of Borrelia burgdorferi
53. Simulation of management strategies for the black-legged tick (Acari: Ixodidae) and the Lyme disease spirochete, Borrelia burgdorferi
54. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite
55. Evaluation of five popular methods for tick removal
56. Methods of evaluating Lyme disease risks using geographic information systems and geospatial analysis
57. Arthropod-borne tularemia in Japan: Clinical analysis of 1374 cases observed between 1924 and 1966
58. Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks
59. Adjuvanted Lyme disease vaccine: A review of its use in the management of Lyme disease
60. Emergence of Lyme disease in Hunterdon County, New Jersey, 1993: A case-control study of risk factors and evaluation of reporting patterns
61. Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine
62. Tick-borne infection caused by Rickettsia africae in West Indies
63. Ticks and tickborne bacterial diseases in humans: An emerging infectious threat
64. Ixodes scapularis (Acari: Ixodidae): Abundance and rate of infection with Borrelia burgdorferi in four state parks in Wisconsin
65. Dynamics of Borrelia burgdorferi transmission by nymphal Ixodes dammini ticks
66. Duration of tick attachment and Borrelia burgdorferi transmission
67. Duration of adult female Ixodes dammini attachment and transmission of Borrelia burgdorferi, with description of a needle aspiration isolation method
68. Prevention of Lyme disease: A review of the evidence
69. Efficacy of amitraz applied to white-tailed deer by the '4-poster' topical treatment device in controlling free-living lone star ticks (Acari: Ixodidae)
70. Systemic treatment of white-tailed deer with ivermectin-medicated bait to control free-living populations of lone star ticks (Acari: Ixodidae)
71. Pharmacokinetics, formulation, and safety of insect repellent N,N-diethyl-3-methylbenzamide (DEET): A review
72. Lyme vaccine: Issues and controversies
73. Short report: Study on the efficacy of a new long-acting formulation of N,N-diethyl-m-toluamide (DEET) for the prevention of tick attachment
74. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease
75. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months
76. Suppression of subadult Ixodes scapularis (Acari: Ixodidae) following removal of leaf litter
77. Effects of selected meteorological factors in diurnal question of Ixodes scapularis and Amblyomma americanum (Acari: Ixodidae)
78. Suppression of Ixodes scapularis (Acari: Ixodidae) nymphs in a large residential community
79. Temporal changes in outer surface proteins A and C of the Lyme-disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice
80. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding
81. Lyme disease in outdoor workers: Risk factors, preventive measures, and tick removal methods
82. Determinants of tick-avoidance behaviors in an endemic area for Lyme disease
83. The cost-effectiveness of vaccination against Lyme disease
84. Doxycycline for tick bites - Not for everyone
85. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites
86. Delayed dissemination of Lyme disease spirochetes from the site of deposition in the skin of mice
87. Vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease
88. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in healthy children and adolescent: A randomized controlled trial
89. Duration of tick attachment as a predictor of the risk of Lyme disease in an area in which Lyme disease is endemic
90. Tick-borne diseases in the United States
91. Temporal correlations between tick abundance and prevalence of ticks infected with Borrelia burgdorferi and increasing incidence of Lyme disease
92. Impact of controlled burns on the abundance of Ixodes scapularis (Acari: Ixodidae)
93. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles
94. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant
95. Rocky Mountain spotted fever in the United States, 1993- 1996
96. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults
97. Clinical and immunological assessment of a candidate Lyme disease vaccine in healthy adults: Antibody persistence and effect of a booster dose at month 12
98. Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine
99. Anaphylaxis from a tick bite
100. Efficacy of antibiotic prophylaxis for prevention of Lyme disease
101. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa
102. Evaluation of whole-cell and OspC enzyme-linked immunosorbent assays for discrimination of early Lyme borreliosis from OspA vaccination
103. Reduced abundance of immature Ixodes dammini (Acari: Ixodidae) following elimination of deer
104. Vaccination as a modality to prevent Lyme disease
105. Practice guidelines for the treatment of Lyme disease
106. Safety and efficacy of DEET and permethrin in the prevention of arthropod attack
107. Borrelia burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection